Medical-tech company Stryker Corp. said Tuesday it has named Timothy Scannell president and chief operating officer, effective Aug. 1.
The company is making the change as David Floyd, group president, orthopaedics, is retiring on June 30, 2019. Scannell started his career with Stryker’s endoscopy business in 1990, serving in sales and marketing roles.
For almost a decade, he has been group president, recently overseeing medsurg and neurotechnology. Stryker shares were not active premarket, but have gained 12% in 2018, while the S&P 500 has gained 4%.
By Ciara Linnane
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).